Chirality - A new era of therapeutics

Mini-Reviews in Medicinal Chemistry

Volumn 7, Issue 5, 2007, Pages 451-460

  Agrawal, Y K ^a   Bhatt, H G ^a   Raval, H G ^b   Oza, P M ^b   Gogoi, P J ^a  

^a NIRMA UNIVERSITY   (India)

^b ANAND PHARMACY COLLEGE   (India)

Author keywords

Chirality; Drug combination; Enantiomers; Pharmacokinetics; Racemic switching; Stereoselectivity

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; CETIRIZINE; CITALOPRAM; DEXTRORPHAN; DISOPYRAMIDE; DOXAZOSIN; ESCITALOPRAM; ESOMEPRAZOLE; ESZOPICLONE; ETHAMBUTOL; FLUOXETINE; IBUPROFEN; KETOPROFEN; LERCANIDIPINE; LEVALBUTEROL; LEVOCETIRIZINE; LEVODOPA; LEVORPHANOL; LOXIGLUMIDE; METHYLPHENIDATE; MORPHINE; NORADRENALIN; OMEPRAZOLE; OXYBUTYNIN; SALBUTAMOL; THALIDOMIDE; UNINDEXED DRUG; VERAPAMIL; ZOPICLONE;

ANALGESIC ACTIVITY; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHIRALITY; CLINICAL TRIAL; DEPRESSION; DIGESTIVE SYSTEM ULCER; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; ENANTIOMER; ENANTIOSELECTIVITY; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; INSOMNIA; IRRITABLE COLON; LEPROSY; LIMB MALFORMATION; LOW DRUG DOSE; MOLECULAR DYNAMICS; OPTIC NEURITIS; PARKINSON DISEASE; RACEMIC MIXTURE; REFLUX ESOPHAGITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; URINE INCONTINENCE; XEROSTOMIA;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; MOLECULAR CONFORMATION; PHARMACEUTICAL PREPARATIONS; STEREOISOMERISM;

EID: 34249791476     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955707780619617     Document Type: Article

References (59)

1. Stinson, S.C. Chem. Eng. News, 2001, 79(40), 79.
2. Stinson, S.C. Chem. Eng. News, 2000, 78(43), 55.
3. http://www.acdlabs.com/publish/pub103/eum03_chirbase.html
4. Armstrong, R.W.; Beau, J.M.; Cheon, S.H.; Christ, W.J.; Fujioka, H.; Ham, W.H.; Hawkins, L.D.; Jin, H.; Kang, S.H.; Kishi, Y.; Martinelli, M.J.; McWhorter, W.W., Jr.; Mizuno, M.; Nakata, M.; Stutz, A.E.; Talamas, F.X.; Taniguchi, J.A.; Tino, J.A.; Ueda, K.; Uenishi, J.I.; White, J.B.; Yonaga, M. J. Am. Chem. Soc., 1989, 111, 7525.
5. Stinson, S.C. Chem. Eng. News, 2001, 79(20), 45.
6. Aitken, R.A.; Kilenyi, S.N. Source and strategy for formation of chiral compounds. In Asymmetric Synthesis, 1st ed., Blackie Academic & Professional, 1995; pp. 64-82.
7. Kalsi, P.S. Chirality In Stereochemistry Conformation and Mechanism, 6th ed., New Age International (p) Limited Publishers, 2005; pp. 15-16.
8. Williams, D.A.; Lemke, T.L. Drug Design and Relationship of Functional Groups to Pharmacological Activity In Foye's Principles of Medicinal Chemistry, 5th ed., Indian edition, Distributed by B.I. Publications Pvt. Ltd., 2005; pp. 50-53.
9. http://www.chirality.ouvaton.org/research.htm
10. Milton, R.C.; Milton, S.C.; Kent, S.B. Science, 1992, 256, 1445.
11. Lipmann, E.; Hotchkiss, R.D.; Dubois, R.J. J. Biol. Chem., 1941, 141, 163.
12. Gross, E.; Morell, J.I. J. Am. Chem. Soc., 1971, 93(18), 4634.
13. Montecucchi, P.C.; de Castiglione, R.; Erspamer, V. Int. J. Pept. Protein Res., 1981, 10, 316.
14. Kreil, G. J. Biol. Chem., 1994, 269, 10967.
15. Heck, S.D.; Siok, C.J.; Krapcho, K.J.; Kelbaugh, P.R.; Thadeio, P.F.; Welch, M.J.; Williams, R.D.; Ganong, A.H.; Kelly M.E.; Lanzetti, A.J. Science, 1994, 266, 1065.
16. Kuwada, M.; Teramoto, T.; Kumagaye, K.Y.; Nakajima, K.; Watanabe, T.; Kawai, T.; Kawakami Y.; Niidome, T.; Sawada, K.; Nishizawa, Y. Mol. Pharmacol., 1994, 46, 587.
17. Pruitti A. Compt. Red., 1886, 103, 134.
18. Easson L.H.; Stedman, E. Biochem. J., 1933, 27, 1257.
19. http://www.pharmacy.umaryland.edu/courses/PHAR531/lectures_old/ chiral_drugs.html.
20. Millership, J.S.; Fitzpatrick, A. Chirality, 1993, 5(8), 573.
21. Stinson, S.C. Chem. Eng. News, 1993, 71, 38.
22. Stinson, S.C. Chem. Eng. News, 1994, 72, 38.
23. Stinson, S. C. Chem. Eng. News, 1995, 73, 44.
24. Vermeulen, N.P.E.; Breimer, D.D. Stereoselectivity in drug and xenobiotic metabolism. In Stereochemistry and Biological Activity of Drugs; Ariens, E.J.; Soudijn, W.; Timmermans, P.B.M.W.M. Eds.; Blackwell Scientific Publications, Oxford, 1983; pp. 33-53.
25. Wainer, L.W.; Drayer, D.E. In Drug Stereochemistry, Analytical Methods and Pharmacology, 2nd ed. Marcel Dekker. 1993.
26. Ariens, E.J. Trends Pharmacol. Sci., 1993, 14, 68.
27. Triggle, D.J. In The Practice of Medicinal Chemistry; Wermuth, C. Ed., Academic Press, 1996; pp. 547-570.
28. Tucker, G.T.; Lennard, M.S. Pharmacol. Ther., 1990, 45, 309.
29. Levy, R.H.; Boddy, A.V. Pharm. Res., 1991, 8, 551.
30. Giacomini, K.M.; Swezey S.E.; Turner-tamiyasu K.; Blaschke T.F. J. Pharmacokinet. Biopharm., 1982, 10, 1.
31. Lima, J.J.; Boudoulas, H.; Blanford, M. J. Pharmacol. Exp. Ther., 1981, 219, 741.
32. Giacomini, K.M.; Cox, B.M.; Blashke, T.F. Life Sci., 1980, 27(13), 1191.
33. Vanhoutte, F.; Vereecke, J.; Carmeliet, E.; Verbeke, N. Naunyn-Schimiedeberg's Arch. Pharmacol., 1991, 344(6), 662.
34. Giacomini, K.M.; Nelson, W.L.; Pershe, R.A.; Valdivieso, L.; Turner-Tamiyasu, K.; Blaschke, T.F. J. Pharmacokinet. Biopharm., 1986, 14(4), 335.
35. Eichelbaum, M.; Gross, A.S. Adv. Drug Res., 1996, 28, 2.
36. Tiggle, D.J. In Cardiovascular Pharmacology; Antonaccio, M. Ed.; Raven Press, 1990; pp. 107-160.
37. Physicians' Desk Reference, 50th Edition, Medical Economics Co. 1996.
38. Know, Y.K.; Triggle, D.J. Chirality, 1991, 3, 393.
39. Van Amsterdam, F.T.M.; Zaagsma, J. Naunyn Schimiedebergs Arch. Pharmacol., 1988, 337, 213.
40. Jim. K.; Harris, A.; Rosenberger, L.B.; Triggle, D.J. Eur. J. Pharmacol., 1981, 76, 67.
41. Van Amsterdam, F.T.M.; Punt, N.C.; Hass, M.; Zaagsma, J. J. Cardiovasc. Pharmacol., 1990, 15, 198.
42. Gross, A.S.; Heuer, B.; Eichelbaum, M. Biochem. Pharmacol., 1988, 37, 4623.
43. Gross, A.S.; Eser, C.; Mikus, G.; Eichelbaum, M. Chirality, 1993, 5, 414.
44. Carr, R.A.; Pasutto, F.M.; Longstreth, J.A.; Foster, R.T. Chirality, 1993, 5, 443.
45. Hubbard, J.W.; Srinivas, N.R.; Quinn, D.; Midha, K.K. J. Pharm. Sci., 1989, 78, 944.
46. http://www.chm.bris.ac.uk/motm/thalidomide/start.html
47. Blaschke, G.; Kratt, H.P.; F-ckentscher, K.; Kohler, F. Arzneim.-Forsch., 1979, 29, 1640.
48. http:/www.chm.bris.ac.uk/motm/thalidomide/first.html
49. Wnendt, S.; Finkam, M.; Winter, W.; Ossig, J.; Raabe, G.; Zwingenberger, K. Chirality, 1996, 8, 390.
50. Stirling, D.; Sherman, M.; Strauss, S. J. Am. Pharm. Assoc., 1997, 37, 306.
51. Thalidomide-The Medical Letter, 40, The Medical Leter, Inc., New Rochelle, NY, 1998; 103.
52. Williams, D.A.; Lemke, T.L. Antimycobacterial Agents In Foye's Principles of Medicinal Chemistry, 5th ed., Indian edition, Distributed by B.I. Publications Pvt. Ltd., 2005; pp. 904-2489.
53. Mikusova, K.; Slayden R.A.; Besra, G.S.; Brennan, P.J. Antimicrob. Agents Chemother., 1995, 39, 2484.
54. Lee, R.E.; Mikusova, K.; Brennan, P.J.; Bersra, G.S. J. Am. Chem. Soc., 1995, 117, 11829.
55. Khoo, K.H.; Douglas, E.; Azadi, P.; Inamine, J.M.; Besra, G.S.; Mikusova, K.; Berennan, P.J.; Chatterjee, D. J. Biol. Chem., 1996, 271, 28628.
56. Rauhi, A.M. Chem. Eng. News, 2003, 81(18), 56.
57. Lindberg, P.; Keeling, D.; Fryklund, J.; Andersson, T.; Lundborg, P.; Carlsson, E. Aliment. Pharmacol. Ther., 2003, 17, 481.
58. Olbe, L.; Carlsson, E.; Lindberg, P. Nat. Rev. Drug Discov., 2003, 2, 132.
59. Heydorn, W.E. Pharm. News., 1995, 2, 19.